Clinical studies

  • Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li Q-X, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA, Szoeke C, Macaulay L, Rowe CC, Villemagne VL, Ames D, Martins RN, Bush AI, Masters CL; AIBL research group.Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer’s disease.Alzheimers Dement 2013; 1 – 9.

  • Le Bastard N, Martin J-J, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging 2010;31: 1867-1876.

  • Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin neuron JJ, Vanmechelen E, De Deyn PP. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging 2008; 29: 1143-1159.
  • Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerström C, Syversen S, Mattsson U-B, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman Å, Blennow K, Wallin A. Intra-individual stability of CSF biomarkers for Alzheimer’s Disease over two years. J Alzheimers Dis 2007; 12: 255-260.
  • Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, Bürger K, Parnetti L, Alessia Lanari, Padovani A, DiLuca M, Bläser M, Ohrfelt Olsson A, Pottel H, Hulstaert F, Vanmechelen E. Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer’s disease and dementia with Lewy bodies. Clin Chem Lab Med 2006; 44: 1472-1480.
  • Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geratr Cogn Disord 2003;15:169-176.
  • Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and Aß42 predicts development of Alzheimer disease in patients with mild cognitive impairment. Acta Neurol Scand 2003; 107 (Suppl 179): 47-51.
  • Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, Vanmechelen E, Förstl H, Kurz A. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol Psychiatr 2003;8:343-347.
  • Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H. Improved discrimination of AD patients using  ß-amyloid(1-42) and tau levels in CSF. Neurology 1999; 52: 1555-1562.
  • Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosc Lett  2001; 297: 187-190.
  • Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, Blennow K. Cerebrospinal fluid markers for Alzheimer’s disease evaluated after acute ischemic stroke. J Alz Disease 2000; 2: 199-206.      
  • Teunissen CE, Dijkstra CD, Jasperse B, Barkhof F, Vanderstichele H, Vanmechelen E, Polman CH,Bö L. Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. Neuropathol Appl Neurobiol 2006; 32: 318-331.
  • Van Everbroeck B, Green AJE, Vanmechelen E, Vanderstichele H, Pals P, Sanchez-Valle R, Corrales NC, Martin J-J, Cras P.  Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2002; 73: 79-81.
  • Höglund K, Thelen KM, Syversen S, Sjögren M, von Bergmann K, Wallin A, Vanmechelen E, Vanderstichele H, Lütjohann D, Blennow K. The effect of simvastatin treatment on the amyloid precursor protein and brain  Cholesterol metabolism in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2005; 19: 256-265.
  • Höglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K. Plasma levels of ß-amyloid(1-40), ß-amyloid(1-42), and total ß-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurology 2004; 61: 333-337.
  • Riemenschneider M, Schmolke M, Lautenschlager N, Vanderstichele H, Vanmechelen E, Guder WG, Kurz A. Association of CSF apolipoprotein E, Aß42 and cognition in Alzheimer’s disease. Neurobiology of Aging 2002; 23: 205-211.
  • Sjögren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, Skoog I, Wallin A, Wahlund L-O, Marcusson J, Nägga K, Andreasen N, Davidsson P, Vanmechelen E, Blennow K. Tau and Aß42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001; 47: 1776-1781.
  • Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granérus A-K, Vanderstichele H, Vanmechelen E, Blennow K. Both total and phosphorylated tau are increased in Alzheimer’s disease. J Neurol Neurosurg Psychiatr 2001; 70: 624-630.
  • Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K. Evaluation of CSF-tau and CSF-Aß42 as diagnostic markers for Alzheimer disease in clinical practice (+ editorial). Arch Neurol 2001; 58: 373-379.
  • Sjögren M, Davidsson P, Gottfries J, Vanderstichele H, Edman A, Vanmechelen E, Wallin  A,  Blennow K. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer’s disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord 2001; 12 : 257-264.
  • Riemenschneider M, Schmolke M, Lautenschlager N, Guder WG, Vanderstichele H, Vanmechelen E, Kurz A. Cerebrospinal beta-amyloid(1-42) in early Alzheimer’s disease: association with apolipoprotein E genotype and cognitive decline. Neurosc Lett 2000; 284: 85-88.
  • Sjögren M, Minthon L, Davidsson P, Granérus A-K, Clarberg A, Vanderstichele H, Vanmechelen E, Wallin A, Blennow K. CSF levels of tau, ß-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of      dementia and normal aging.  J Neural Transm 2000; 107: 563-579.
  • Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K. Cerebrospinal fluid tau and Aß42 as predictors of development of Alzheimer’s disease  in patients with mild cognitive impairment. Neurosc Lett 1999; 273: 5-8.
  • Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999. 53:1488-1494.
  • Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K . Cerebrospinal fluid  ß-amyloid apoE in Alzheimer disease: differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurology  1999; 56: 673-680.
  • Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Bürger K, Hampel H, Frölich L, Henn F, Falkai P, Rüther E, Jahn H, Luckhaus C, Perneczky R, Schmidtke K, Schröder J, Kessler H, Pantel J, Gertz H-J, Vanderstichele H, de Meyer G, Shapiro F, Wolf S, Bibl M, Wiltfang J. Amyloid ß peptides in plasma in early diagnosis of Alzheimer’s disease: A multicenter study with multiplexing.  Exp Neurol 2010; 223: 366 – 370.
  • Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K. Evaluation of plasma Aß40 and Aß42 as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging 2010;31: 357-367.
  • Blennow K, De Meyer G, Hansson O, Minthon L, Wallin A, Zetterberg H, Lewczuk P, Vanderstichele H, Vanmechelen E, Kornhuber J, Wiltfang J and KND-study group. Evolution of Aß42 and Aß40 Levels and Aß42/Aß40 ratio in plasma during progression of Alzheimer’s Disease: a multicenter assessment. J Nutr Health Aging 2009;13: 205 – 208.
  • Olsson A, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Unaltered plasma levels of ß-amyloid(1-40) and ß-amyloid(1-42) upon stimulation of  human platelets. Dement Geriatr Cogn Disord 2003; 16: 93-97.
Neurodegeneration ⇑